Navigation Links
A Drug That Carries a Lower Risk of Weight Gain Than AstraZeneca's Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
Date:4/22/2008

Seroquel's Successor, Seroquel XR, Will Earn a 16 Percent Patient Share in

the Bipolar Disorder Market by 2016, According to a New Report from

Decision Resources

WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that carries a lower risk of weight gain than AstraZeneca's Seroquel and has both antimanic and antidepressant effects would earn a 30 percent patient share in the treatment of bipolar disorder, according to surveyed psychiatrists.

The new report entitled Bipolar Disorder: Although Bipolar Mania Is a Crowded Market, Physicians Continue to Demand Better Treatment finds that surveyed psychiatrists indicate that they would prescribe AstraZeneca's Seroquel XR to 20 percent of their bipolar disorder patients, following its approval for the indication in 2009. As a result, Seroquel XR is forecasted to earn a 16 percent patient share in the U.S. bipolar disorder market in 2016.

The report also finds that Seroquel XR will earn gold-standard status for treatment of bipolar disorder in 2011 as interviewed psychiatrists indicate that Seroquel XR's delivery profile -- once-daily dosing -- will be marginally superior to that of Seroquel immediate-release. Although surveyed psychiatrists indicated that lithium and Eli Lilly's Zyprexa have advantages in efficacy, lithium and Zyprexa have disadvantages in safety, tolerability and/or delivery when compared to Seroquel.

"Interviewed psychiatrists report that Seroquel can sometimes require twice-daily dosing for sustained efficacy," said Kate Hohenberg, director at Decision Resources. "As a result, Seroquel XR narrowly edges out its parent compound to become the new gold standard because of its incremental advantage in delivery."

About the Report

Bipolar Disorder: Although Bipolar Mania Is a Crowded Market, Physicians Continue to Demand Better Treatment is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Obesity During Pregnancy Carries Bigger Price Tag
2. Survival rates appear lower for scalp and neck melanoma than for other sites
3. Hospital Care in Singapore Now Available to American Patients at Pre-Negotiated, In-Network Rates Far Lower than Comparable Services in the U.S.
4. Bioponic Phytoceuticals Announces Curecumin(TM) May Lower Heart Failure Risk
5. AUDIO from Medialink and Apple Products Research and Education Council: New Research -- Adults Who Eat Apples, Apple Juice Have Healthier Diets and Lower Risk for Metabolic Syndrome
6. Risk of Womens Heart Attack or Stroke Appears to Be Lowered by DASH Diet
7. Blocking the effect of inflammation-causing cells lowered prostate cancer cells invasion
8. Adults who eat apples, drink apple juice have lower risk for metabolic syndrome
9. Medco Acquires Majority Interest in Europa Apotheek; Delivering Innovation, Clinical Quality and Lower-Cost Solutions to Fast-Growing German Health Care Market
10. Lowering Blood Pressure Improves Brain Hemorrhage Outcomes
11. Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... , ... January 22, 2017 , ... Zifam Pinnacle, an ... the world, recently met with big-name retail buyers at the January ECRM Trade Show ... efficacy and uses the utmost safety standards in all of its creations to help ...
(Date:1/21/2017)... FL (PRWEB) , ... January 21, 2017 , ... Caronlab ... recently attended the January ECRM Trade Show in Hilton Head, SC, where it benefited ... reputation for the quality of its beauty and wellness products. At this trade show, ...
(Date:1/21/2017)... ... 21, 2017 , ... Seamild, the largest manufacturer of oats in China, is ... and founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, ... believes it is a move to sow the seed of good karma. Buddhism spirit ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates (NCMA) ... their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, ... add this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... -- ResMed (NYSE: RMD ), BMC (Peking, ... Winter Haven, Florida ) gaben heute bekannt, dass ... globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt haben. BMC und ... im Tausch gegen Lizenzgebühren an ResMed gestattet, und ResMed ... in Florida anhängige Rechtsverfahren zwischen ...
(Date:1/23/2017)... 2017 InDex Pharmaceuticals Holding AB (publ) today ... congress of the European Crohn,s and Colitis Organisation (ECCO). The ECCO ... focus on inflammatory bowel disease (IBD). The congress is held in ... ... to again having been selected to present data at the largest ...
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 ... "US Clinical Laboratory Testing Market By Type of Test (Tumor, ... Independent), & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS ... ... an attractive destination for healthcare services, market segments, especially clinical ...
Breaking Medicine Technology: